YARDLEY, Pa. – Eurand, a global specialty pharmaceutical company, recently conducted a webinar titled: “The $10 Billion Gap: Leveraging Taste-Masking Technologies to Meet Global Patient Needs”, presented by Troy Harmon, Vice President of Business Development, and Andrew Thompson, Vice President of Commercial Operations.
The webinar, which highlighted Eurand’s proprietary taste-masking technology platform, was hosted by Pharmaceutical Business Review, an online journal that attracts a subscription audience of more than 100,000 worldwide pharmaceutical professionals. The webinar offered an overview of taste-masking trends as presented by Global Data, a leading business information company providing business information, reports and services. Targeted to a global audience of pharmaceutical professionals, the presentation demonstrated Eurand’s leadership in the application of taste-masking technologies, with specific case studies highlighting formulation expertise across OTC and Rx products in a variety of therapeutic indications.
“Participating with both Global Data and Pharmaceutical Business Review gave us the opportunity to reach a global audience of pharmaceutical professionals who are seeking knowledge about product taste-masking,” said Thompson, who oversees Eurand’s pharmaceutical technology business outside of North America.
Harmon, who is responsible for Eurand’s business development, licensing, and commercial efforts in North America, discussed the applicability of Eurand’s taste-masking technologies to a variety of oral administration forms, including liquids and suspensions, as well as capabilities to address odor masking associated with certain drugs.
“The webinar was a great way to share our technology expertise and product successes in taste-masking, and to exchange information and interact with our customer targets,” said Harmon.
View the archived webinar online at: http://www.business-review- webinars.com/webinar.php?chan=Pharma&id=3659905ef698197cebfd754e9d33d4be
If you’d like to learn more about this topic or to schedule a meeting or interview with Andrew Thompson or Troy Harmon, please contact Troy Harmon at +1 267-759-9340 or email Troy at troy.harmon@eurand.com.
You can also contact Eurand via our website at: www.eurand.com/contact.html
About AdvaTab®
Eurand’s AdvaTab technology utilizes proprietary granulation and tabletting processes to provide an orally disintegrating tablet with superior mouth-feel attributes. When combined with Eurand’s Microcaps ®taste-masking technology, AdvaTab ODTs are one of the leading orally disintegrating tablet systems available to the pharmaceutical industry today. Key features of AdvaTab include: excellent mouth feel; tablets that can be packaged in bottles or blisters; rapid disintegration in the oral cavity; ability to incorporate microencapsulated drug particles; and the capacity to incorporate larger drug doses than conventional ODT technologies. To obtain a free AdvaTab prototype from a licensing representative, visit the company’s website atwww.eurand.com/contact.html.
About Microcaps®
Eurand’s microencapsulation technology, known as Microcaps®, employs versatile and precise coating techniques to encapsulate individual drug particles using solvent and aqueous-based coacervation. This includes taste and odor masking, customized release profiles, conversion of liquids to solids and the separation of incompatible materials. Microcaps® is incorporated in more than 12 marketed products.
About Eurand
Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.
